solo para uso en investigación

Cabozantinib (XL184) inhibidor de Met/VEGFR2

Name: Cabozantinib (XL184)
Brand: Selleck Chemicals
SKU: S1119
Rating: 5 (166 reviews)

Cat. No.S1119

Un potente inhibidor de VEGFR2 con una IC50 de 0,035 nM, Cabozantinib (XL184) también inhibe c-Met, Ret, Kit, Flt-1/3/4, Tie2 y AXL con una IC50 de 1,3 nM, 4 nM, 4,6 nM, 12 nM/11,3 nM/6 nM, 14,3 nM y 7 nM en ensayos sin células, respectivamente. Induce apoptosis dependiente de PUMA en células de cáncer de colon a través de la vía de señalización AKT/GSK-3β/NF-κB.

Cabozantinib (XL184) VEGFR inhibidor Chemical Structure

Estructura química

Peso molecular: 501.51

Saltar a

Control de calidad

Lote: Pureza: 99.99%

99.99

Dianas relacionadas	EGFR PDGFR FGFR c-Met Src MEK CSF-1R FLT3 HER2 c-Kit
Otros VEGFR Inhibidores	SAR131675 SU 5402 Cediranib (AZD2171) Vatalanib (PTK787) 2HCl Anlotinib (AL3818) Dihydrochloride Linifanib (ABT-869) Apatinib (YN968D1) Apatinib (YN968D1) mesylate Ki8751 ZM 323881 HCl

Cultivo celular, tratamiento y concentración de trabajo

Líneas celulares	Tipo de ensayo	Concentración	Tiempo de incubación	Formulación	Descripción de la actividad	PMID
E98NT	Growth Inhibition Assay	0.01-10 μM		DMSO	IC50=89 nM	23484006
SNU-5	Growth Inhibition Assay				IC50= 19 nM	21926191
Hs746T	Growth Inhibition Assay				IC50=9.9 nM	21926191
SNU-1	Growth Inhibition Assay				IC50=5223 nM	21926191
SNU-16	Growth Inhibition Assay				IC50=1149 nM	21926191
MDA-MB-231	Growth Inhibition Assay				IC50= 6421 nM	21926191
U87MG	Growth Inhibition Assay				IC50=1851 nM	21926191
H441	Growth Inhibition Assay				IC50=21700 nM	21926191
H69	Growth Inhibition Assay				IC50=20200 nM	21926191
PC3	Growth Inhibition Assay				IC50=10800 nM	21926191
MTC-TT	Growth Inhibition Assay				IC50=0.04 + 0.03 μM	21470995
MZ-CRC	Growth Inhibition Assay				IC50> 5 μM	21470995
TPC-1	Growth Inhibition Assay				IC50=0.06 + 0.02 μM	21470995
NIH-3T3/TPR-Met	Function assay				Inhibition of cell proliferation in mouse NIH-3T3/TPR-Met cells, IC50 = 1 μM.	24996144
BA/F3	Growth inhibition assay				Inhibition of TEL-fused VEGFR2 (unknown origin) expressed in mouse BA/F3 cells assessed as cell growth inhibition, GI50 = 0.003 μM.	26652860
BaF3	Growth inhibition assay		48 hrs		Inhibition of TEL-fused Ret S891A mutant (unknown origin) expressed in mouse BaF3 cells assessed as cell growth inhibition after 48 hrs by MTT assay, GI50 = 0.01 μM.	26652860
BA/F3	Growth inhibition assay		48 hrs		Inhibition of wild type TEL-fused RET (unknown origin) expressed in mouse BA/F3 cells assessed as cell growth inhibition after 48 hrs by MTT assay, GI50 = 0.05 μM.	26652860
TT	Growth inhibition assay		10 days		Inhibition of RET C634W mutant in human TT cells assessed as cell growth inhibition after 10 days by MTT assay, GI50 = 0.12 μM.	26652860
BA/F3	Growth inhibition assay		48 hrs		Inhibition of TEL-fused Ret V804M mutant (unknown origin) expressed in mouse BA/F3 cells assessed as cell growth inhibition after 48 hrs by MTT assay, GI50 = 0.89 μM.	26652860
BaF3	Growth inhibition assay		48 hrs		Inhibition of TEL-fused Ret V804L mutant (unknown origin) expressed in mouse BaF3 cells assessed as cell growth inhibition after 48 hrs by MTT assay, GI50 = 0.91 μM.	26652860
Nthy-ori 3-1	Cytotoxicity assay		10 days		Cytotoxicity against human Nthy-ori 3-1 cells after 10 days by MTT assay, GI50 = 4.93 μM.	26652860
BAF3	Function assay	0.01 to 10 uM	1 hr		Inhibition of TEL-fused wild type Ret (unknown origin) phosphorylation at Y1062/Y905 expressed in mouse BAF3 cells at 0.01 to 10 uM after 1 hr by Western blot analysis	26652860
TT	Function assay		4 hrs		Inhibition of autophosphorylation of RET C634W mutant at Y905 in human TT cells at 1 uM after 4 hrs by Western blot analysis	26652860
BAF3	Function assay	0.01 to 10 uM	1 hr		Inhibition of TEL-fused Ret S891A mutant (unknown origin) phosphorylation at Y1062/Y905 expressed in mouse BAF3 cells at 0.01 to 10 uM after 1 hr by Western blot analysis	26652860
BAF3	Function assay	0.01 to 10 uM	1 hr		Inhibition of TEL-fused Ret S891A mutant (unknown origin) expressed in mouse BAF3 cells assessed as suppression of phosphorylation of PLCgamma at Y783 at 0.01 to 10 uM after 1 hr by Western blot analysis	26652860
BAF3	Function assay	0.01 to 10 uM	1 hr		Inhibition of TEL-fused Ret S891A mutant (unknown origin) expressed in mouse BAF3 cells assessed as suppression of phosphorylation of Shc at Y317 at 0.01 to 10 uM after 1 hr by Western blot analysis	26652860
TT	Function assay	1 to 10 uM	4 hrs		Inhibition of RET C634W mutant in human TT cells assessed as suppression of PLCgamma phosphorylation at Y783 at 1 to 10 uM after 4 hrs by Western blot analysis	26652860
TT	Function assay	1 to 10 uM	4 hrs		Inhibition of RET C634W mutant in human TT cells assessed as suppression of ERK phosphorylation at T202/Y204 at 1 to 10 uM after 4 hrs by Western blot analysis	26652860
TT	Function assay	1 to 10 uM	4 hrs		Inhibition of RET C634W mutant in human TT cells assessed as suppression of AKT phosphorylation at T308/S473 at 1 to 10 uM after 4 hrs by Western blot analysis	26652860
TT	Function assay	1 uM			Inhibition of Ret-driven oncogenic transformation of human TT cells at 1 uM by soft agar assay	26652860
TT	Function assay	1 uM	4 hrs		Inhibition of autophosphorylation of RET C634W mutant at Y1062 in human TT cells at 1 uM after 4 hrs by Western blot analysis	26652860
TT	Apoptosis assay	1 uM	96 hrs		Induction of apoptosis in human TT cells expressing Ret C634W mutant at 1 uM after 96 hrs by annexinV/PI staining-based flow cytometric analysis	26652860
PC3	Function assay		1 to 3 hrs		Inhibition of c-Met phosphorylation in human PC3 cells incubated for 1 to 3 hrs, IC50 = 1.9 μM.	26717201
MDA-MB-231	Function assay		1 to 3 hrs		Inhibition of AXL phosphorylation in human MDA-MB-231 cells incubated for 1 to 3 hrs, IC50 = 5 μM.	26717201
BAF3	Function assay		1 to 3 hrs		Inhibition of FLT3 (unknown origin) phosphorylation transfected in mouse BAF3 cells incubated for 1 to 3 hrs, IC50 = 7.5 μM.	26717201
MDA-MB-231	Function assay		1 to 3 hrs		Inhibition of KIT (unknown origin) phosphorylation transfected in human MDA-MB-231 cells incubated for 1 to 3 hrs, IC50 = 42 μM.	26717201
BA/F3	Function assay		48 hrs		Inhibition of KDR (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay, IC50 = 0.014 μM.	26874741
Sf21	Function assay		15 mins		Inhibition of recombinant His-tagged human KDR expressed in insect Sf21 cells preincubated for 15 mins followed by substrate addition measured after 20 mins by HTRF assay, IC50 = 0.016 μM.	26874741
BA/F3	Function assay		48 hrs		Inhibition of KIF5B/RET (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay, IC50 = 0.19 μM.	26874741
BA/F3	Function assay		48 hrs		Inhibition of KIF5B/RET (unknown origin) expressed in mouse BA/F3 cells assessed as reduction in cell viability after 48 hrs by Cell titre glo-based luminescence assay, IC50 = 0.19 μM.	26874741
BA/F3	Antiproliferative assay		72 hrs		Antiproliferative activity against mouse BA/F3 cells expressing TPR-Met after 72 hrs by CCK8 assay, IC50 = 0.0219 μM.	27068889
Sf21	Function assay		60 mins		Inhibition of wild type N-terminal GST-tagged recombinant human RET (658 residues) expressed in insect Sf21 cells using poly(Glu,Tyr)4:1 as substrate incubated for 60 mins by ELISA, IC50 = 0.003 μM.	27131066
Sf21	Function assay		60 mins		Inhibition of N-terminal GST-tagged recombinant human RET V804M mutant (658 residues) expressed in insect Sf21 cells using poly(Glu,Tyr)4:1 as substrate incubated for 60 mins by ELISA, IC50 = 0.811 μM.	27131066
BaF3	Function assay		72 hrs		Inhibition of CCDC6-RET (unknown origin) expressed in mouse BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by SRB/CCK-8 assay, IC50 = 0.889 μM.	27131066
BaF3	Function assay		72 hrs		Inhibition of CCDC6-RET (unknown origin) expressed in mouse BaF3 cells assessed as inhibition of cell proliferation after 72 hrs by SRB/CCK-8 assay, IC50 = 0.889 μM.	27131066
Ba/F3	Function assay				Inhibition of RET (unknown origin) transfected in mouse Ba/F3 cells assessed as reduction in cell viability by CellTiter-Glo luminescence assay, GI50 = 0.07 μM.	27814560
TT	Function assay				Inhibition of RET C634W mutant in human TT cells assessed as reduction in cell viability by CellTiter-Glo luminescence assay, GI50 = 0.26 μM.	27814560
Ba/F3	Function assay				Inhibition of RET V804M mutant (unknown origin) transfected in mouse Ba/F3 cells assessed as reduction in cell viability by CellTiter-Glo luminescence assay, GI50 = 0.74 μM.	27814560
Nthy-ori 3-1	Cytotoxicity assay				Cytotoxicity against human Nthy-ori 3-1 cells assessed as reduction in cell viability by CellTiter-Glo luminescence assay, GI50 = 2.92 μM.	27814560
HepG2	Antiproliferative assay		72 hrs		Antiproliferative activity against human HepG2 cells after 72 hrs by MTT assay, IC50 = 0.012 μM.	28412159
EBC1	Antiproliferative assay		72 hrs		Antiproliferative activity against human EBC1 cells after 72 hrs by MTT assay, IC50 = 0.0514 μM.	28412159
H1299	Growth inhibition assay		72 hrs		Growth inhibition of human H1299 cells incubated for 72 hrs by CCK8 assay, IC50 = 1.919 μM.	28651979
MCF7	Growth inhibition assay		72 hrs		Growth inhibition of human MCF7 cells incubated for 72 hrs by CCK8 assay, IC50 = 2.889 μM.	28651979
A549	Growth inhibition assay		72 hrs		Growth inhibition of human A549 cells incubated for 72 hrs by CCK8 assay, IC50 = 4.205 μM.	28651979
T47D	Growth inhibition assay		72 hrs		Growth inhibition of human T47D cells incubated for 72 hrs by CCK8 assay, IC50 = 4.448 μM.	28651979
H460	Growth inhibition assay		72 hrs		Growth inhibition of human H460 cells incubated for 72 hrs by CCK8 assay, IC50 = 5.669 μM.	28651979
HuH7	Antiproliferative assay		48 hrs		Antiproliferative activity against human HuH7 cells after 48 hrs by MTT assay, IC50 = 4.348 μM.	29057042
A498	Antiproliferative assay		48 hrs		Antiproliferative activity against human A498 cells after 48 hrs by MTT assay, IC50 = 8.456 μM.	29057042
NCI-H727	Antiproliferative assay		48 hrs		Antiproliferative activity against human NCI-H727 cells after 48 hrs by MTT assay, IC50 = 14.01 μM.	29057042
BAF3	Antiproliferative assay		72 hrs		Antiproliferative activity against mouse BAF3 cells harboring TRP-MET after 72 hrs by CCK-8 assay, IC50 = 0.024 μM.	29146452
A549	Cytotoxicity assay	10 uM	72 hrs		Cytotoxicity against human A549 cells at 10 uM after 72 hrs by Incucyte live-cell imaging analysis	29407963
A673	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells	29435139
DAOY	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells	29435139
Saos-2	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells	29435139
BT-37	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells	29435139
RD	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells	29435139
SK-N-SH	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells	29435139
BT-12	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells	29435139
NB1643	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells	29435139
OHS-50	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells	29435139
Rh41	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells	29435139
A673	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)	29435139
U-2 OS	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells	29435139
OHS-50	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells	29435139
Rh41	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells	29435139
SJ-GBM2	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells	29435139
SK-N-MC	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells	29435139
NB-EBc1	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells	29435139
LAN-5	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells	29435139
Rh18	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells	29435139
SJ-GBM2	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells	29435139
TC32	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells	29435139
Saos-2	qHTS assay				qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells	29435139
EBC1	Antiproliferative assay		72 hrs		Antiproliferative activity against human EBC1 cells after 72 hrs by MTT assay, IC50 = 0.0048 μM.	30248654
MKN45	Antiproliferative assay		72 hrs		Antiproliferative activity against human MKN45 cells after 72 hrs by MTT assay, IC50 = 0.0069 μM.	30248654
SNU5	Antiproliferative assay		72 hrs		Antiproliferative activity against human SNU5 cells after 72 hrs by MTT assay, IC50 = 0.0121 μM.	30248654
BAF3	Function assay		72 hrs		Inhibition of TPR-tagged met (unknown origin) expressed in mouse BAF3 cells assessed as inhibition of cell proliferation after 72 hrs by MTT assay, IC50 = 0.01986 μM.	30248654
NCI-H460	Antiproliferative assay		72 hrs		Antiproliferative activity against human NCI-H460 cells after 72 hrs by MTT assay, IC50 = 0.0401 μM.	30248654
MGHU3	Antiproliferative assay		72 hrs		Antiproliferative activity against human MGHU3 cells after 72 hrs by CellTiter-Glo assay	30309671
RT112	Antiproliferative assay		72 hrs		Antiproliferative activity against human RT112 cells after 72 hrs by CellTiter-Glo assay	30309671
Haga clic para ver más datos experimentales de líneas celulares

Información química, almacenamiento y estabilidad

Peso molecular	501.51	Fórmula	C₂₈H₂₄FN₃O₅	Almacenamiento (Desde la fecha de recepción)	3 años-20°Cpolvo
Nº CAS	849217-68-1	Descargar SDF		Almacenamiento de soluciones madre	1 año-80°Cen disolvente 1 mes-20°Cen disolvente
Sinónimos	BMS-907351			Smiles	COC1=CC2=C(C=CN=C2C=C1OC)OC3=CC=C(C=C3)NC(=O)C4(CC4)C(=O)NC5=CC=C(C=C5)F

Solubilidad

In vitro
Lote:

DMSO : 100 mg/mL (199.39 mM)
(El DMSO contaminado con humedad puede reducir la solubilidad. Usar DMSO fresco y anhidro.)

Water : Insoluble

Ethanol : Insoluble

Calculadora de Molaridad

Masa	Concentración	Volumen	Peso molecular
=	×	×

Calculadora de Dilución Calculadora de Peso Molecular

In vivo Lote:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

Calculadora de formulación in vivo (Solución clara)

Paso 1: Introduzca la información a continuación (Recomendado: Un animal adicional para tener en cuenta la pérdida durante el experimento)

Dosis: mg/kg Peso promedio de los animales: g Volumen de dosificación por animal:μL Número de animales:

Paso 2: Introduzca la formulación in vivo (Esto es solo la calculadora, no la formulación. Por favor, contáctenos primero si no hay una formulación in vivo en la sección de Solubilidad.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Resultados del cálculo:

Concentración de trabajo: mg/ml;

Método para preparar el líquido maestro de DMSO: mg fármaco predissuelto en μL DMSO ( Concentración del líquido maestro mg/mL, Por favor, contáctenos primero si la concentración excede la solubilidad del DMSO del lote del fármaco. )

Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadirμL PEG300, mezclar y clarificar, luego añadirμL Tween 80, mezclar y clarificar, luego añadir μL ddH₂O, mezclar y clarificar.

Método para preparar la formulación in vivo: Tomar μL DMSO líquido maestro, luego añadir μL Aceite de maíz, mezclar y clarificar.

Nota: 1. Por favor, asegúrese de que el líquido esté claro antes de añadir el siguiente disolvente.
2. Asegúrese de añadir el (los) disolvente(s) en orden. Debe asegurarse de que la solución obtenida, en la adición anterior, sea una solución clara antes de proceder a añadir el siguiente disolvente. Se pueden utilizar métodos físicos como el vórtice, el ultrasonido o el baño de agua caliente para ayudar a la disolución.

Mecanismo de acción

Targets/IC₅₀/Ki	VEGFR2/KDR (Cell-free assay) 0.035 nM c-Met (Cell-free assay) 1.3 nM Axl (Cell-free assay) 7 nM
In vitro	Cabozantinib (XL184) tiene una débil actividad inhibidora contra RON y PDGFRβ con una IC50 de 124 nM y 234 nM, respectivamente, y tiene baja actividad contra FGFR1 con una IC50 de 5,294 μM. A baja concentración (0,1-0,5 μM), es suficiente para inducir una marcada inhibición de la fosforilación constitutiva e inducible de Met y su señalización posterior resultante en células MPNST, e inhibir la migración e invasión de células MPNST inducidas por HGF. Este compuesto también induce una marcada inhibición de la fosforilación de Met y VEGFR2 en células endoteliales de vena umbilical humana (HUVECs) estimuladas por citocinas. Aunque no tiene un efecto significativo sobre el crecimiento de células MPNST a 0,1 μM, XL184 a 5-10 μM inhibe significativamente el crecimiento de células MPNST.
In vivo	El tratamiento con Cabozantinib (XL184) a 30 mg/kg en ratones RIP-Tag2 con tumores espontáneos de islotes pancreáticos interrumpe el 83% de la vasculatura tumoral, reduce los pericitos y los manguitos de membrana basal vacíos, causa hipoxia intratumoral generalizada y una extensa apoptosis de las células tumorales, y ralentiza el rebrote de la vasculatura tumoral después de la retirada del fármaco, de manera más significativa en comparación con XL999, que bloquea VEGFR pero no c-Met, lo que lleva a una reducción de solo el 43% en la vascularización, lo que sugiere que la inhibición concurrente de VEGFR y otras tirosina quinasas receptoras (RTK) funcionalmente relevantes amplifica la inhibición de la angiogénesis. Este compuesto también disminuye la invasividad de los tumores primarios y reduce la metástasis. A 30 mg/kg/día, abroga significativamente el crecimiento y la metástasis de xenoinjertos de MPNST humanos en ratones SCID. La administración de XL184 induce una inhibición dosis-dependiente del crecimiento tumoral en modelos de tumores de mama, pulmón y glioma, en asociación con una disminución de la proliferación de células tumorales y endoteliales, así como un aumento de la apoptosis. Una dosis oral única es suficiente para inducir una inhibición sostenida del crecimiento tumoral en ratones portadores de tumores MDA-MB-231 y ratas portadoras de tumores C6 a 100 mg/kg y 10 mg/kg, respectivamente.
Referencias	[1] https://pubmed.ncbi.nlm.nih.gov/21613405/ [2] https://pubmed.ncbi.nlm.nih.gov/21540237/ [3] https://pubmed.ncbi.nlm.nih.gov/21926191/

Aplicaciones

Métodos	Biomarcadores	PMID
Western blot	p-MET / p-ERK / p-AKT p-MET(Y1234/1235) / MET / p-EGFR(Y1068) / EGFR / p-Gab1(Y627) / Gab1 / p-AKT(S473) / p-ERK / p-EIF4E	29520051
Immunofluorescence	α-tubulin	29520051
Growth inhibition assay	Cell viability	23661005

Información del ensayo clínico

(datos de https://clinicaltrials.gov, actualizado el 2024-05-22)

Número NCT	Reclutamiento	Condiciones	Patrocinador/Colaboradores	Fecha de inicio	Fases
NCT06156410	Recruiting	Ewing Sarcoma\|Osteosarcoma	Children''s Hospital of Philadelphia\|Children''s Hospital Colorado\|Exelixis\|Alex''s Lemonade Stand Foundation	October 24 2023	Phase 1
NCT05249114	Active not recruiting	Neuroendocrine Tumors	Providence Health & Services\|Exelixis\|Advanced Accelerator Applications SA	December 28 2022	Phase 1
NCT05444933	Completed	Advanced Renal Cell Carcinoma	Ipsen	September 16 2022	--

Soporte técnico

Instrucciones de manipulación

Tel: +1-832-582-8158 Ext:3

Si tiene alguna otra consulta, por favor deje un mensaje.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):